Archive for November, 2008
Paragraph IV On Trial
November 19th, 2008
in Pharmaceuticals / Biotech / Life Sciences, Regulatory & Compliance |
Benchmark and refine your Hatch-Waxman litigation trial advocacy skills at this engaging mock trial event
Renowned patent litigators experienced in representing both generic
and brand name drug manufacturers will work through a complex
MOCK TRIAL based on a real world ANDA filing:
YANKEE BRANDED PHARMACEUTICALS V. METRO GENERIC
PHARMACEUTICALS (see inside on page 3 for the detailed fact pattern)
Hone your advocacy and litigation skills in:
• Communicating with the judge in a clear and concise manner while
presenting complex technical and scientific information to the court
• Developing a cohesive and scientifically-supported theory to address
issues raised by infringement, validity and inequitable conduct claims
during trial
• Addressing prior art and discrepancies in the patented product’s
prosecution history in a manner that supports the theory of your case
• Handling expert and fact witnesses on the stand during direct and cross
examination when testifying about sensitive product and company details
Billions of dollars – in lost or gained profits – are at stake during a
patent infringement case. Learn and witness firsthand what strategies
your peers are employing to successfully litigate Paragraph IV disputes
as a Hatch-Waxman case unfolds before your eyes…
At the annual Paragraph IV Conference in April, you voiced a need for a conference dedicated solely to exploring the specific challenges faced by counsel when actually litigating Hatch-Waxman, Paragraph IV disputes. Based on your feedback and the success of our On Trial series of events, ACI has developed Paragraph IV On Trial – an interactive mock trial event based on a patent infringement case between a brand name and generic drug manufacturer.
Structured as an actual trial based on an ANDA filing involving a compound and a formulation patent, our experienced faculty of patent litigators will conduct live demonstrations of direct and cross examinations, as you witness an entire, detailed, Paragraph IV trial, beginning with the banging of the gavel and concluding with closing statements.
Dissecting the ins and outs of a Paragraph IV case from start to finish, learn from these experts as they delve into the key issues at stake during trial, including:
• Infringement – how to lay the proper foundation through your expert in order to build your case
• Obviousness and anticipation – tactics for handling prior art testimony and addressing
arguments of validity and invalidity
• Secondary considerations – strategies for effectively presenting technical experts and
communicating complex, scientific and technical information to the court
• Inequitable conduct – dealing with testifying patent law experts and complicated prosecution records during trial
Also, don’t miss this rare opportunity to hear from two distinguished panels, one comprised of 6 renowned jurists experienced in patent litigation and the other composed of 6 in-house IP counsel, representing both brand name and generic manufacturers, as they share with you commentary and insights into what factors they consider when deciding and engaging in Paragraph IV litigation.
2nd National Forum on BUSINESS METHOD PATENTS
November 19th, 2008
in Intellectual Property, Pharmaceuticals / Biotech / Life Sciences |
Protecting and Capitalizing on Innovations in the
Financial Services, Software, and Insurance Industries
Obtain proven strategies and expert advice for:
• Employing new defenses against patent trolls in the wake
of Bilski, Comiskey, and other recent cases
• Identifying patentable processes in your organization to maximize
licensing opportunities
• Assessing the validity of your BMPs based on emerging court
decisions and PTO regulations
• Putting a plan in place to protect your proprietary information
in the absence of patentability
• Speeding up the prosecution process: tips for creating
a PTO-friendly application
• Prior art searches: where to look when mining key resources–
and when to stop
BUSINESS METHOD PATENTS
Ten years after the landmark State Street decision, the Court of Appeals for the
Federal Circuit is reconsidering just what is patentable subject matter and what is
not. The Court’s decision in In re Bilski will likely have a very significant impact
on the financial services, software, and insurance industries due to the prevalence
of business method patents in those industries. It is critical that corporate and
outside counsel that handle patents for companies in these industries be prepared
for the changes that In re Bilski and other recent decisions are bringing to all
aspects of business method patents, from prosecution to litigation to licensing.
Add to this the difficulties of prior art searches involving business method patents
and looming Congressional patent reform legislation and it is clear that the
challenges and opportunities in the area of business method patents have never
been greater.
American Conference Institute’s 2nd National Forum on Business Method Patents
will bring together leading corporate IP and patent counsel from the financial
services, software, and insurance industries as well as expert outside counsel to
provide you with the knowledge, strategies, and insights that you need to:
• Successfully bring and defend against business method patent infringement claims
• Win the battle over the determination of damages
• Structure effective licensing agreements post-Quanta
• Establish and maintain ownership of intellectual property through alternatives
to business method patents
• Use inter partes reexamination as an effective defensive tool
• Conduct accurate valuations of business method patents
IN PHARMACEUTICAL MANAGING LEGAL RISKS MANUFACTURING OUTSOURCING
November 18th, 2008
in Pharmaceuticals / Biotech / Life Sciences |
Negotiating crucial contract provisions to protect proprietary information,
improve quality control procedures, and ensure FDA compliance
Leading in-house counsel, regulators, and expert attorneys
will show you how to:
• COORDINATE with the FDA’s field office when a recall occurs as the result
of a manufacturing defect
• COLLABORATE with internal compliance teams to ensure that inspection
requirements are complied with expeditiously
• ENSURE that the manufacturer is operating in accordance with GMPs
• ENGAGE in effective due diligence practices when contracting with CMOs
• MITIGATE the risk of violating international laws including FCPA and the
Patriot Act when contracting with off-shore manufacturers
• ALLOCATE risks and liabilities among the parties through careful negotiation
of the indemnification and insurance provisions
• SET clear and practical limitations on damages during the contract negotiation
Benchmark your internal manufacturing processes against the
industry’s best practices for effective contract negotiation,
maintaining GMP compliance, and protecting IP
There is more government scrutiny than ever before on pharmaceutical manufacturing
outsourcing. As big pharma turns to off shore manufacturing in an effort to cut costs, we are witnessing increased recalls, costly litigation, and misappropriation of IP. The key is to think about every potential outcome at the drafting and negotiation phase and make sure that your intentions behind the underlying contract are executed through out the term. Along with the FDA’s increased scrutiny over U.S. and overseas manufacturing plants, quality control within the company must be completely reassessed from the ground up.
With so many moving parts, a true collaborative effort is necessary among the supply chain managers, quality control managers, contract professionals, and many others. As a result, there is more oversight—and a greater margin of error—involved in pharmaceutical manufacturing outsourcing than any other type of outsourcing. Whatever part of the process you are involved in, it is imperative to develop a full understanding of the way your internal role functions with others in your company and ultimately at the manufacturer’s.
Focusing on your key concerns, American Conference Institute has developed Managing Legal Risks in Pharmaceutical Manufacturing Outsourcing. In an effort to develop the most valuable program, we have secured the participation of regulators, in-house counsel from major companies, and expert outside counsel who will guide you through the painstaking but necessary process of ensuring that your contracts are drafted, negotiated, and executed in the most favorable and protective manner. Specific highlights of this timely event include:
• Allocating liability and responsibility for a recall at the contractual phase
• Training manufacturers on the magnitude and potential consequences of an FDA inspection
• Ensuring that the manufacturer is in compliance with GMPs at all times during
the manufacturing process
• Engaging in ample communication with the manufacturer to ensure quality control,
best practices, and timely delivery of products
• Articulating the importance of your audit right and anticipating push-back
from the manufacturer
• Assessing the effectiveness of collaborating with CMOs
• Implementing safeguards to ensure that the manufacturer will protect your proprietary information
• Identifying potential risks when sourcing products from third parties for the purpose
of negotiating the indemnification clause
You can also add significant value to your experience by attending our Master Class:
The “Win-Win” Pharmaceutical Manufacturing Outsourcing Agreement: Practical and Ethical Drafting and Negotiating Strategies. This high-level master class will introduce the use of a hypothetical fact pattern to demonstrate creative, effective, and ethical strategies for negotiating deals with local as well as off-shore manufacturers.
Advertisign and Promotions for the pharmaceutical industry
November 17th, 2008
in Advertising & Marketing, Pharmaceuticals / Biotech / Life Sciences |
Leading in-house counsel, former government regulators, and expert attorneys in the field will help you to:
• DEVELOP programs and practices to protect the promotion program
from claims of off-label promotion
• DEFEND against and INITIATE competitor complaints
• SAFEGUARD the promotions program against claims of illegal
or inappropriate communications
• DEFINE current regulatory obligations for pharmaceutical advertising
programs employing new media
• EXAMINE statutory changes and potential legislation that may cause
upheaval in an established marketing program
• IMPLEMENT required FDAAA provisions into existing compliance programs
• IMPROVE existing communications programs for pre-approval marketing
• ADDRESS the potential ramifications of a Supreme Court preemption
decision on pharmaceutical advertising
“Pharmaceutical companies will spend more
than $1 billion on direct marketing in 2008…”
Brandweek, April 10, 2008
As drug and device manufacturers devote more financial resources to Direct to
Consumer advertising, government and public scrutiny over these promotions
only intensifies. The manner of communication, in addition to the ad’s content,
is being examined by all levels of government- federal and state legislators, FDA
and FTC, DOJ and OIG- as well as public interest groups and direct
competitors. A violation of any of the myriad of regulations and processes will
undoubtedly result in consequences including astounding fines, criminal
investigations, and significant civil litigation.
Maintaining a profitable and compliant promotions program is a daily challenge
for both in-house attorneys and outside law firms. New media allows for the
development of revolutionary marketing programs, yet the risk of delving into offlabel
marketing remains a frequent problem. Innovative communication and
education programs designed to reach subscribers and patients need to be carefully
monitored to protect a company from potential liability. The cost and time
associated with a program review from inception to implementation is staggering,
and the increase in required review and warnings are expensive and long. The list
of challenges to practitioners in the field is almost unending.
While the regulatory and legislative path has rarely been clear, today it is more
confusing than ever. Implementing FDAAA regulations into a review program
continues to be arduous, and provides more questions than answers. The status of
FDA draft guidance on reprints remains a mystery, as does the FDA’s ability to
pre-approve advertisements. The industry continues to fend off fierce competitor
complaints and product liability cases at an alarming rate that are based on
promotional and non-promotional communications. Finally, pharmaceutical and
device companies are preparing for all potential outcomes from the pending
Supreme Court preemption decisions.
American Conference Institute invites senior and experienced practitioners to
participate in the 7th Corporate Counsel Forum on Advertising and Promotions
for the Pharmaceutical Industry. The faculty includes government and legislative
specialists who have devoted their career to FDA and pharmaceutical law issues,
as well as high level in-house attorneys who are resolving these challenges daily.
The program will provide up to the minute updates on legislation, judicial
decisions, and regulatory trends that are essential to a successful and investigation
free promotion program.
Add value to your experience with out Post-Conference Workshop: Pharma Ad
Claims and Promotions Compliance Bootcamp: Developing Key Advertising
and Marketing Strategies that Can Withstand Government Scrutiny. Our
expert faculty will provide an essential framework for marketing and promotions
programs that avoid triggering a potential FDA review.
8th National Conference on Reducing Legal Risks in the Sale and Marketing of Medical Devices
November 17th, 2008
in Advertising & Marketing, Litigation, Pharmaceuticals / Biotech / Life Sciences |
American Conference Institute’s 8th National Conference on Reducing Legal Risks in the Sale and Marketing of Medical Devices.
FortifYing fraud and abuse compliance efforts
in The Face of increasing government scrutiny
17 experienced in-house attorneys and compliance officers from these companies:
Animas • Bard • Bayer • BD • Biomet • Covidien • Cyberonics
GE Healthcare • Hospira • Medtronic • Roche Diagnostics • Siemens
…as well as 9 government enforcers and regulators and leading outside counsel will help you:
• REASSESS your compliance program as a result of the Deferred Prosecution Agreements
• DISSEMINATE peer-reviewed studies of off-label uses and AVOID FCA/FFDCA scrutiny
of off-label promotion
• AVOID anti-kickback red flags when handling activities involving prescribers and purchasers, including grants, gifts, entertainment, and free goods
• DESIGN compliant policies and procedures for consulting arrangements, including
FMV determination and needs assessments
• RESPOND to government inquiries and NEGOTIATE and IMPLEMENT Corporate
Integrity Agreements
• REDUCE the risk of FCPA investigations and violations
• OVERCOME the current coverage, coding, and payment challenges with device reimbursement
• EXAMINE the appropriate circumstances for discounting, bundling and price concessions
• IDENTIFY legal parameters of DTC marketing, including “new media”
• TRACK state legislative initiatives on device promotion and HARMONIZE inconsistent
state obligations
Congress is focusing on disclosure and transparency in the device
industry like never before and enforcement authorities are
stepping up the number and aggressiveness of investigations of
device companies’ doctor relationships.
There has never been a more important time to attend the industry’s best
forum on enhancing sale and marketing compliance functions.
Increased focus on the sale and marketing activities of device manufacturers is here:
DPAs/CIAs/NPAs, monitors, and consulting arrangements…
The Senate bill on disclosure to patients of doctors’ financial ties to device companies…
Huge settlements as a result of improper gifts and giveaways…
Federal prosecutors targeting medical device companies in FCPA investigations…
New guidance on the dissemination of peer-reviewed studies of off-label uses…
And these developments are in addition to the uncertainty device companies already face
in creating effective compliance programs (in areas such grants, entertainment, and free
goods), as well as the continuing obligation to keep tabs on the traditional sales and
marketing activities that have triggered enforcement in the past, i.e. off-label promotion,
direct-to-consumer marketing.
As device companies continue to adapt to the “new world order” of scrutiny in their attempt to stay on the right side of law, it’s not enough to just have a compliance program in place. In response, ACI is proud to introduce its 8th National Conference on Reducing Legal Risks in the Sale and Marketing of Medical Devices. Through a faculty of 17 distinguished in-house counsel and compliance officers, 9 government enforcers and regulators, and leading outside counsel, this conference will provide attendees with the strategies needed to not only develop an ethical compliance infrastructure, but also the ability to show commitment to compliance through intensive training, supervision, and monitoring, as well as the skills needed to remediate before the prosecutors come knocking and the knowledge on when and how to cooperate if they do.
PLUS, add value to your attendance by also registering for the
Master Class on Compliance Process Management:
Implementing and Expanding Effective Monitoring and Auditing Controls
as Part of Your Overall Compliance Program
Nov. 19, 2008 – 9 a.m. – 12 p.m.
Tags: Legal conferences, Litigation strategies
No Comments »
BAD FAITH DEFENSE COUNSEL SUMMIT
November 13th, 2008
in Insurance & Reinsurance |
Minimizing and Resolving Bad Faith Claims and Litigation
Develop your expertise on:
• Implementing practices to recognize and prepare against the “bad faith set-up”
• Utilizing reverse bad faith or comparative bad faith as a defense
• Limiting liability by preventing fraudulent joinder of a claims representative
• Developing and establishing a winning trial theme for your case
• Best practices for limiting discovery and preserving attorney-client privilege
Are you looking for a closed door event where you and your peers can benchmark
your defense strategies and discuss effective practices to successfully minimize
exposure to the onslaught of bad faith claims without fear that your adversary is
sitting right next to you? Well, look no further!
At American Conference Institute’s Bad Faith Litigation Defense Counsel
Summit, industry leaders from the top insurance companies and insurance defense
firms will provide you with the latest cutting-edge developments in an area of law
that is constantly changing. Not only will you gain practical strategies for dealing
with allegations of bad faith that arise during claims handling and, in litigation;
you will network with, our exceptional faculty of experienced in-house
professionals and seasoned private practice attorneys. Topics include:
• Successfully presenting evidence of a “bad faith set-up” to a jury
• Defense tactics for prohibiting or capping punitive damages
• Avoiding overzealous litigation practices and “litigation conduct” claims of bad faith
• Effectively assessing the “win- ability” of your case before going to trial
• Cost-effective approaches for using bad faith experts
This comprehensive and information-packed event is one you cannot afford to miss!
Take this opportunity to get your questions answered by some of the leading bad
faith litigators and to network with insurance industry executives from around the
country.
Health & Safety Crisis Management and Prevention
November 13th, 2008
in Energy & Resources, Healthcare |
for Chemical and Petroleum Companies
Mitigating Risk through Contingency Planning and Ongoing Compliance
Get legal and practical guidance that you can apply to your daily work:
• Improving your contingency planning: Reducing the risk of injuries, fatalities
and legal liability
• Managing a crisis: Coping with injuries, fatalities and multiple investigations
• Preparing for more inspections and enforcement: Expansion of the Refinery National
Emphasis Program to chemical plants
• Evaluating the worst case costs of a crisis: Criminal and civil exposure
• Refi ning your media and PR crisis communication: Avoiding legal and
reputational damage
• Preparing for an OSHA inspection: Lessons learned
• Undergoing OSHA inspections: Do’s and don’ts for employee interviews,
inspector access and more
• Minimizing the financial, legal and reputational costs of OSHA citations
In addition to the human toll, poor contingency planning
can result in OSHA citations, staggering civil damages
and criminal prosecution. Moreover, your organization’s
reputation and bottom line could be at stake. With heightened
enforcement by OSHA and other agencies, and plaintifffriendly
decisions, you need to re-assess all aspects of your crisis
management, prevention and PSM compliance programs.
Given the poor level of PSM compliance uncovered during
inspections under the “Petroleum Refi nery Process Safety
Management National Emphasis Program”, OSHA has extended
the duration of this program indefi nitely and will likely expand it
to chemical manufacturing plants.
Given the poor level of PSM compliance uncovered during
inspections under the “Petroleum Refi nery Process Safety
Management National Emphasis Program”, OSHA has extended
the duration of this program indefi nitely and will likely expand it
to chemical manufacturing plants.
• Update on expansion of the Refi nery National Emphasis
Program, CFATs and more
• Anticipating the worst case costs of a crisis: Civil
and criminal exposure
• Upgrading your contingency planning to reduce the risk
of injuries, fatalities and legal liability
• Managing a crisis: Minimizing injuries, fatalities and dealing
with multiple investigations
• Refi ning your media and PR crisis communication strategy
• Planning for an OSHA inspection under the Refi nery
National Emphasis Program
• Managing OSHA inspections: Employee interviews,
inspector access and your internal investigation
• Reducing the fi nancial, legal and reputational costs
of OSHA citations
• Creating and preserving privilege of self-audit results
3rd Annual Prescription DRUG PRICING BOOT CAMP
November 13th, 2008
in Pharmaceuticals / Biotech / Life Sciences |
American Conference Institute’s 3rd Annual Prescription DRUG PRICING BOOT CAMP
Intensive training in essential pricing concepts, methodologies,
and strategies relative to key government payor programs
Leaders in government pricing and reimbursement will drill you in the core
competencies of prescription drug pricing related to government payor programs and help you:
• UNDERSTAND how government prices are established and how the rebate
system works
• MASTER implementation of the final Medicaid rebate rule
• DEFINE key pricing terms
• MAKE SENSE of confusing pricing calculations
• MASTER key pricing concepts and learn how one price may affect another:
- AMP, AWP, WAC, BP, WAMP, CPIU, ASP, FCP and non-FAMP
MASTER THE FUNDAMENTALS OF PRICING
FOR GOVERNMENT PAYOR PROGRAMS
Pricing calculations, price reporting and compliance under government payor
programs such as Medicaid, Medicare, VA/DoD and PHS can be confusing and
time consuming. Add to this the recent changes under the DRA, and even the
most seasoned pricing and reimbursement veterans are left with questions. Such
uncertainty is particularly dangerous today when any miscalculation may lead to
government scrutiny, investigations, and enforcement actions.
But finding expert information on government pricing can prove even more
difficult than pricing itself. To fill this void, ACI has created Rx Drug Pricing
Boot Camp. Now in its third year, this program provides drug manufacturers,
PBMs, plans, and pharmacies with the critical information they need to effectively
and efficiently manage government pricing. ACI’s Boot Camp is the training
program you need to ensure that your pricing group and other related
departments are well-versed in critical pricing concepts and methodologies. No
other conference breaks down the fundamentals of prescription drug pricing in
such an easy-to-understand and comprehensive format.
In addition to intensive training in core pricing methodologies and concepts,
ACI’s Rx Drug Pricing Boot Camp, also provides the opportunity to network
with fellow pricing colleagues. With 80% of attendees coming from drug
manufacturers, PBMs, plans and pharmacies, this is the perfect opportunity to
find out what other companies are struggling with and how they are overcoming
the challenges they face on a day-to-day basis.
Structuring, Negotiating and Managing Pharma/Biotech Collaborative Agreements
November 13th, 2008
in Pharmaceuticals / Biotech / Life Sciences |
American Conference Institute’s
11th Advanced Forum on
Structuring, Negotiating and Managing Pharma/Biotech
Collaborative Agreements
Allocating Rights, Responsibilities & Rewards in
Licensing, Strategic Alliances and Partnering Deals
Leading in-house counsel, licensing and business development executives and expert
attorneys in the field will share their insights and experiences on how to:
• LEVERAGE intellectual property and draft favorable exclusivity provisions
• ANTICIPATE the potential impact of M & A activity on your transaction
• NEGOTIATE co-development rights
• PROTECT rights relating to future developments and improvements
• EVALUATEviable compensation structures
• MINIMIZE risks through partner selection and due diligence
• ENSURE effective alliance management
• NEGOTIATE hotly contested issues with universities
• AVOIDthe top pitfalls of international deals
Ensure your collaborations are structured
to maximize the returns from product
development and commercialization
With approximately $20 billion in annual sales coming off patent this year (reported in
IMS Health’s 2008 Global Pharmaceutical Market and Therapy Forecast, 11/1/07), the
stakes in negotiating and maintaining lucrative licensing and collaborations could not be
higher. Drug makers need to invest in building product pipelines, and partnering is a key
part of R&D strategies for maintaining profits and fighting the plague of competition
from generic manufacturers. And with many of the major companies cutting overhead,
partnering becomes an even more attractive way for them to jumpstart research while at
the same time trimming costs. For biotech firms, this climate provides opportunities for
negotiating attractive financial terms, as evidenced in the recent upfront payments of as
much as $100 million.
In its 11th installment, ACI’s Advanced Forum on Pharma/Biotech Collaborative
Agreements provides you with the unparalleled opportunity to meet, network and learn
from experienced practitioners who every day successfully navigate their way through these complex agreements. Featuring business and legal representatives from 17 leading
companies and universities, you will hear from them the most effective strategies for
tackling the key challenges confronting you daily when negotiating and drafting
agreements, including:
· Retaining valuable product rights
· Securing licenses without granting potentially lucrative co-development options
· Factoring M&A into ANY negotiation
· Drafting clauses creating favorable exclusivity rights and minimizing litigation
in the wake of MedImmune and Quanta
· Selecting the right partners, deal structure, and compensation analysis
· Negotiating competitive terms with academic institutions
Continue your conference experience by attending one of the Master Classes:
· Sustaining a Successful Collaboration Through Effective Alliance Management
· The “Win-Win” Collaborative Agreement: Practical and Ethical Negotiating
and Drafting Strategies
This year’s program will provide the opportunity to continue your discussions with
colleagues and speakers at the close of the first day, in a relaxed environment over cocktails.
With so much at stake and the ability to network with the outstanding faculty and
participants, you can see why many industry professionals return to this event year after year.
Global Executive Liability Insurance
November 12th, 2008
in Insurance & Reinsurance |
THE Roadmap for Assessing Risk, Coordinating Policies and Accounting for
Country-Specific Considerations in a Time of Increasing Global Litigation and Enforcement
Hear from top brokers, carriers and other D&O and E&O experts on:
• How increased corporate governance, recent mass/class litigation and newly ramped-up
regulatory efforts outside the US are impacting coverage of D&Os abroad
• Mastering the challenges associated with underwriting, quoting and binding out-of-country
• Coverage solutions for covering corporate executives in foreign jurisdictions where
indemnification is prohibited by law
• Avoiding negative tax consequences in countries where non-admitted policies are allowed
• Implications of local legal requirements and restrictions on Board and executive liability
• Establishing an on-the-ground framework for working with partners around the globe
for effective underwriting and claims management
• Strategies for averting potential exposures for brokers and others with respect to
possible E&O claims as a result of ineffective executive liability coverage
Increased globalization, changing regulatory regimes
and growing use of litigation have altered the playing
field for corporate executives outside of the US . . . are
your policies keeping pace?
D&O coverage for US foreign subsidiaries and operations is in the spotlight like
never before. D&O liability lawsuits are being brought in foreign jurisdictions at
an unprecedented rate. Regulators around the world are stepping up their
demands for compliance with local laws. Many jurisdictions are embracing
so-called US-style litigation, notably in the areas of securities, environmental, and
antitrust. Class and consumer action legislation is evolving rapidly in a number
of countries, including the UK, France, Italy, Australia and the Netherlands,
to name a few.
These developments are hitting many US brokers and insurers with the realization
that coverage for D&Os abroad may not be sufficient – and in some cases, because
of local laws and recent developments, may actually be non-existent. Leading
carriers and brokers have been actively working to become intricately familiar with
jurisdictions around the world where the presence of US foreign subs and ops,
coupled with a rise in local litigation and regulation, mean that coverage has to be
reworked, rethought and reoffered in a form that accounts for and covers rapidlyevolving
risks.
In response, ACI created this groundbreaking conference on Global Executive
Liability Insurance. In developing this conference, ACI conducted extensive
research with the leading brokers, carriers and other experts in this area, to deliver
a conference that covers all the key issues, including:
• How the rise of class, mass, representative, group and collective actions outside
of the U.S. is developing and impacting D&O underwriting and claims
• Solutions for covering corporate executives in foreign jurisdictions where
indemnification is prohibited by law
• Paying proceeds legally into foreign jurisdictions: procedures to follow
to avoid possible complications
• Practical strategies for managing multi-country claims arising from the same incident
To ensure you get complete coverage of all the issues, we’ve assembled a faculty that
includes lawyers from key jurisdictions all over the world, plus seasoned brokers
and carriers with hands-on experience in dealing with global executive liability.
We think you’ll agree that it’s two days out of the office extremely well spent!
